The use of high‐dose intravenous immunoglobulins in Guillain‐Barré syndrome

A patient with severe Guillain-Barré syndrome responded to treatment with high-dose intravenous immunoglobulins. It is suggested, on the basis of recent case reports, that immunoglobulins may have an important rôle in the future treatment of this immune-mediated disease.